Education and Training
Cardiology - The Children's Hospital of Philadelphia, Philadelphia, PA
BPharm in Pharmaceutical Sciences - The Hebrew University of Jerusalem, Israel
PhD in Pharmaceutical Sciences - The Hebrew University of Jerusalem, Israel
MS in Pharmaceutical Sciences - The Hebrew University of Jerusalem, Israel
Titles and Academic Titles
Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
R. Iyer, J. L. Croucher, M. Chorny, J. L. Mangino, I. S. Alferiev, R. J. Levy, V. Kolla, G. M. Brodeur, Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Lett 360, 205-212 (2015).
I. S. Alferiev, R. Iyer, J. L. Croucher, R. F. Adamo, K. Zhang, J. L. Mangino, V. Kolla, I. Fishbein, G. M. Brodeur, R. J. Levy, M. Chorny, Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials 51, 22-29 (2015).
J. E. Tengood, I. S. Alferiev, K. Zhang, I. Fishbein, R. J. Levy, M. Chorny, Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media. Proc Natl Acad Sci U S A 111, 4245-4250 (2014).
M. Chorny, I. Fishbein, J. E. Tengood, R. F. Adamo, I. S. Alferiev, R. J. Levy, Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J 27, 2198-2206 (2013).
M. Chorny, I. S. Alferiev, I. Fishbein, J. E. Tengood, Z. Folchman-Wagner, S. P. Forbes, R. J. Levy, Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery. Pharm Res 29, 1232-1241 (2012).
I. Fishbein, M. Chorny, I.S. Alferiev, R.F. Adamo, R.J. Levy: Prevention of restenosis with stent-based vascular gene delivery: gene-eluting stents. Coronary artery restenosis: causes, treatment and clinical outcomes. Amir S. Lotfi (eds.). Nova Science Publishers, New York, Page: 239-261, 2014.
J.E. Tengood, I. Fishbein, R.J. Levy, M. Chorny: Nanomedicines for Restenosis Therapy. Frontiers in Nanobiomedical Research: Volume 3. Handbook of Nanobiomedical Research (Fundamentals, Applications and Recent Developments, v2: Applications in Therapy). V. Torchilin (eds.). World Scientific Publishing, London, 2: 39-87, Oct 2014 Notes: ISBN: 978-981-4520-64-5.
I. Fishbein, M. Chorny, I.S. Alferiev, R.J. Levy: Site Specific Controlled Release for Cardiovascular Disease - Translational Directions. Fundamentals and Applications of Controlled Release Drug Delivery. J. Siepmann, R.A. Siegel, M.J. Rathbone (eds.). Springer, New York, Page: 445-492, 2012.
E. Cohen-Sela, M. Chorny, G. Golomb: Nanoparticles for the treatment of restenosis. Nanoparticles for Pharmaceutical Applications. A.J. Domb, Y. Tabata, M.N.V.R. Kumar, S. Farber (eds.). ASP, Stevenson Ranch, CA, Page: 123-134, 2006.
M. Chorny, H. Cohen-Sacks, I. Fishbein, H.D. Danenberg, G. Golomb: Biodegradable nanoparticles as drug delivery systems for parenteral administration. Tissue Engineering and Novel Delivery Systems. M.J. Yaszemski, D.J. Trantolo, K. Lewandrowski, V. Hasirci, D.E. Altobelli, D.L. Wise (eds.). Marcel Dekker, New York, Page: 393-422, 2003.
I. Fishbein, M. Chorny, I. Gati, L. Rabinovich, G. Golomb: Drug delivery systems for the treatment of restenosis. Biomaterials and Bioengineering Handbook. D.L. Wise (eds.). Marcel Dekker, New York, Page: pp. 313-335, 2000.
Posters and Presentations
R. Iyer, J.L. Croucher, M. Chorny, J.L. Mangino, I. Alferiev, R.J. Levy, V. Kolla, G.M. Brodeur: Nanoparticle delivery of an SN38 conjugate is more effective than Irinotecan in a mouse model of Neuroblastoma. American Association for Cancer Research Annual Meeting 2015, April 18-22, 2015, Philadelphia, PA 2015.
I. Fishbein, R.F. Adamo, M. Chorny, I.S. Alferiev, R.J. Levy: Induction of pro-healing macrophages through the reprogramming of invading monocytes: a new antirestenotic strategy. 3rd International Conference on Translational Medicine, November 3-5, 2014, Las Vegas, NV 2014.
R. Iyer, J.L. Croucher, M. Chorny, J.L. Mangino, I. Alferiev, R.J. Levy, V. Kolla, G.M. Brodeur: Biodegradable Nanoparticles Loaded with a Rapidly Activatable SN38 Prodrug Effectively Inhibit Growth of Neuroblastoma (NB) Xenografts. Advances in Neuroblastoma Research 2014 Conference, May 13-16, 2014, Cologne, Germany 2014.
P.C. Naha, A.A. Zaki, E. Hecht, M. Chorny, P. Chhour, W. Witschey, H.I. Litt, A. Tsourkas, D.P. Cormode: Dextran coated bismuth-iron oxide nanoparticle as a novel contrast agent for both computed tomography and magnetic resonance imaging. ACS 2014 Colloid & Surface Science Symposium, June 22-25, 2014, Philadelphia, PA 2014.
P.C. Naha, A.A. Zaki, E. Hecht, M. Chorny, P. Chhour, W. Witschey, H.I. Litt, A. Tsourkas, D.P. Cormode: Dextran coated bismuth-iron oxide nanohybrid contrast agent for computed tomography and magnetic resonance imaging. World Molecular Imaging Congress 2014, September 17-20, 2014, Seoul, Korea 2014.
S.P. Forbes, I.S. Alferiev, R.F. Adamo, M. Chorny, R.J. Levy, I. Fishbein: Prevention of Restenosis through Ad-iNOS Gene Therapy Combined with Supplementation of Tetrahydrobiopterin and Arginine. 16th Annual Meeting of the American Society of Gene & Cell Therapy, May 15-18, 2013, Salt Lake City, UT. 2013.
M. Chorny: Magnetically targeted drug delivery to stented blood vessels. 3rd International Conference on Pharmaceutics and Novel Drug Delivery Systems, April 8-10, 2013, Chicago, IL. 2013.
J.E. Tengood, I.S. Alferiev, R.J. Levy, M. Chorny: Functionalization of endothelial cells with biodegradable magnetic nanoparticles for targeted delivery. The TERMIS-Americas 2013 Annual Conference & Exposition, November 10-13, 2013, Atlanta, GA 2013.
J.E. Tengood, I.S. Alferiev, I. Fishbein, R.J. Levy, M. Chorny: Measuring Intracellular Degradation of Polylactide-Based Magnetic Nanoparticles Using FRET 16th Annual Meeting of the American Society of Gene & Cell Therapy, May 15-18, 2013, Salt Lake City, UT. 2013.
I. Fishbein, R.F. Adamo, J.M. Connolly, S. Redlich, K.A. Clark, R.A. Corrales, M. Chorny, S.P. Forbes, R.J. Levy: Ex-Vivo Transduced Monocytes as Gene Delivery Vehicles to Restenotic Arteries. 16th Annual Meeting of the American Society of Gene & Cell Therapy, May 15-18, 2013, Salt Lake City, UT. 2013.
"Nanoparticles for site-specific delivery of small-molecule drugs and biotherapeutics to injured vasculature", 5th International Conference on Clinical & Experimental Cardiology, Philadelphia, PA, USA, April 2015.
"Monitoring disassembly of biodegradable nanoparticles designed for targeted delivery", 5th International Conference on Clinical & Experimental Cardiology, Philadelphia, PA, USA, April 2015.
"SN-38 prodrug-loaded nanoparticles for neuroblastoma therapy", International Conference on Significant Advances in Biomedical Engineering, Philadelphia, PA, USA, April 2015.
"Real-time analysis of nanoparticle disassembly in vascular cells and biomimetic media using Foerster Resonance Energy Transfer", Symposium on Nanoparticles for Biomedical Applications: Improving Performance and Design Through Mechanistic Studies, Ben-Gurion University of the Negev, Beer-Sheva, Israel, October 2014.
"Magnetic targeting for site-specific delivery of genes and cells to stented blood vessels", Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, October 2013.
"Magnetically targeted drug delivery to stented blood vessels", 3rd International Conference on Pharmaceutics and Novel Drug Delivery Systems, Chicago, IL, USA, April 2013.
Awards and Honors
2011, Certificate of Research Excellence from the American Heart Association in recognition of outstanding dedication and achievement in heart disease and stroke research
2009, New Investigator Award from the Ethel Brown Foerderer Fund for Excellence
2006, Outstanding presentation in basic research, The Children's Hospital of Philadelphia/The Joseph Stokes, Jr. Research Institute
2001, Superpharm Ph.D. student distinction award
1997, Goldhaber Family prize for academic achievements
Editorial and Academic Positions
2013-present, Journal of Nanotechnology in Diagnosis and Treatment, Editorial board member
2015-present, Journal of Microencapsulation
2014-present, Journal of Biomedical Nanotechnology
2013-present, ACS Nano
2012-present, Expert Opinion on Drug Delivery
2012-present, Molecular Therapy
2012-present, Molecular Pharmaceutics
2012-present, Joint research project proposals for the Institute for Drug Research, the Hebrew University of Jerusalem (Israel) and the Fraunhofer-Gesellschaft Institute (Germany)
2011-present, Grant applications for The Henry Smith Charity, London, UK
2011-present, Pharmaceutical Research
2011-present, Acta Biomaterialia
2011-present, Drug Development & Industrial Pharmacy
2009-present, International Journal of Nanomedicine
2009-present, Current Cancer Drug Targets
2005-present, Langmuir Archives of Medical Research
2003-present, Journal of Pharmaceutical Sciences
Academic and Institutional Committees
2013-present, Pediatric Cardiology Scholarship Oversight Committee
2012-present, Center for Targeted Therapeutics and Translational Nanomedicine, reviewer of pilot grant applications
2012-present, Reviewer of T32 applications for the Division of Cardiology
2011-present, Bioengineering Graduate Group
Leadership and Memberships
Memberships in Professional Organizations
2010-present, Controlled Release Society
2009-present, American Society of Gene and Cell Therapy
2008-present, American Heart Association
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.